Inspira Technologies announces validation of advanced blood labs of HYLA

Inspira Technologies (IINN) announced the validation in the Company’s advanced blood labs of its Next-Generation Standalone HYLA System. Designed to function independently of the Company’s respiratory support devices, this new configuration allows Inspira Technologies to penetrate the broader approximately $50B heart-lung surgery market immediately upon clearance. In advanced bench testing, the system demonstrated 94.2% accuracy for the continuous optical measurement of Partial Pressure of Carbon Dioxide, a performance level that aligns with clinical needs. The validation data confirms that the HYLA optical sensor tracks real-time patient status with high fidelity. The observed 94.2% accuracy for pCO2 is a critical achievement, demonstrating concordance with gold-standard blood gas analyzers within a tight 7 mmHg threshold. By providing continuous, non-invasive visibility into a patient’s metabolic status, HYLA eliminates the ‘blind spots’ associated with intermittent blood draws, potentially reducing complications during heart-lung machine and extracorporeal membrane oxygenation procedures. This validation marks a strategic evolution for the HYLA platform. By decoupling the sensor from Inspira Technologies’ life-support hardware, the Company is advancing a standalone system capable of integrating into any existing operating room or ICU workflow. This ‘universal compatibility’ strategy significantly expands Inspira Technologies’s total addressable market and activates a high-margin, recurring revenue model based on the sale of disposable optical sensors and modular software upgrades.